Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Levi Sokol, Kim M. Hirshfield, Chandrika Jeyamohan, Srilatha Simhadri, Janice M. Mehnert, Lorna Rodriguez-Rodriguez, Husam Al-Hraishawi, Shridar Ganesan, Sharon R. Pine, Atul Kulkarni, Suzie Chen, Man Lung Teo, Eileen White, Siraj M. Ali
Publikováno v:
Clinical Cancer Research. 23:5631-5638
Purpose: Many patients with BRAFV600E mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective treatment strate
Autor:
Daniel I. Isaac, Ryan Ramaekers, Mark Erlander, Manish R. Sharma, Lawrence Mendelsohn, Maya Ridinger
Publikováno v:
Cancer Research. 81:425-425
Introduction: Chemotherapy in combination with targeted agents are standard-of-care options for first and second-line treatment of metastatic colorectal cancer (mCRC) patients. Second-line treatment of KRAS-mutated mCRC confers a dismal patient outco
Autor:
Ellen Richmond, Eugene Trowers, Nicholas J. Shaheen, Blake A. Gibson, Gary Della'Zanna, Bhaskar Banerjee, Chiu Hsieh Hsu, Jessica A. Martinez, H-H. Sherry Chow
Publikováno v:
Cancer Prevention Research. 9:528-533
Prior research strongly implicates gastric acid and bile acids, two major components of the gastroesophageal refluxate, in the development of Barrett's esophagus and its pathogenesis. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been sho
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
Tanios Bekaii-Saab, Errin Samuelsz, Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Mark G. Erlander, Heinz-Josef Lenz
Publikováno v:
Cancer Research. 80:CT235-CT235
Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with respo
Autor:
Temitope O. Keku, Hanna K. Sanoff, Sushant A. Patil, Michael S. Lee, Kelli Hammond, Todd Auman, Ganiraju C. Manyam, Sara R. Selitsky, Scott Kopetz, Joel S. Parker, Federico Innocenti, Amber N. McCoy
Publikováno v:
Cancer Research. 80:A03-A03
Background: F. nucleatum is an oral anaerobe aberrantly found in up to 43% of CRCs. F. nucleatum presence is associated with additional known prognostic variables, including BRAF mutation and immune infiltration. In nonmetastatic CRC, F. nucleatum is